NCT06280508View on ClinicalTrials.gov

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Interventions
DRUG

Adebrelimab, Apatinib, Gemcitabine, cisplatin

Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER